Trump's Super Intelligence Force: a 120-day report, a rebrand, and no new powers

President Donald Trump announced a "Super Intelligence Force" to coordinate federal work on advanced AI, with Director of National Intelligence Jay Clayton as the administration's AI czar, according to India Today. The panel reports to Trump and White House Chief of Staff Susie Wiles, and has 120 days — roughly until early February — to deliver an assessment of AI's risks and opportunities. It will also review incident-reporting systems for breaches and hacks, and coordinate federal engagement with consumers, public interest groups, religious organisations, critical infrastructure operators and the companies building these systems.

One clause in that mandate does more work than the rest: the Force is to recommend ways to strengthen the government's response *under existing powers*. That is not a regulator. It is an inventory of authorities the executive branch already has, assembled by a committee with no statutory basis of its own, announced on Truth Social rather than in a document that carries legal consequence. The announcement followed a White House accord in which leading tech firms "pledged to uphold their responsibilities to the public" — voluntary commitments, which is the instrument the United States has leaned on since 2023.

The membership is the clearest statement of intent. Vice chairs are FTC Chairman Andrew Ferguson, Under Secretary of War for Research and Engineering Emil Michael and Office of Personnel Management Director Scott Kupor; members include Vice President JD Vance, Defense Secretary Pete Hegseth and Treasury Secretary Scott Bessent, with venture capitalist David Sacks and former Secretary of State Condoleezza Rice as outside advisers. Defense procurement, fiscal policy, the federal workforce, consumer protection. Notably absent from the announced roster is a dedicated technical safety seat. The one lever here with genuine teeth is Ferguson's: FTC consumer-protection authority is already being used against AI products, and it does not require new legislation.

Then there is the vocabulary. Trump has argued the word "artificial" makes the technology "sound fake," and the State Department's Bureau of International Organization Affairs has instructed staff to use "super intelligence" and "SI" in all remarks and press material, per an email obtained by the Associated Press. US representatives then used "SI" at a UN Security Council session where technology executives were calling for checks on AI development. Renaming a technology changes neither its capabilities nor its failure modes. It is worth logging precisely because it costs nothing and looks like action.

The framing is explicitly competitive. "The risk of not being first is high," Clayton said. Trump has ruled out working with Xi Jinping on AI governance, arguing it would make it harder for US firms to outbuild Chinese rivals: "We're leading now over China and everyone else, and I want to keep it that way." The lead is real — on our own quality and cybersecurity indices, Anthropic and OpenAI sit ahead of the field. But the margin is thinner than the rhetoric, especially in open-weight models, where GLM, Qwen, DeepSeek and Kimi are close behind. And there is an awkward loop in the logic: the Force's own remit includes cross-cutting incident reporting, which is exactly the kind of mechanism that only works when adversaries participate.

Our reading: judge this by the February report, not the press release. Three tests. Does it name concrete thresholds and a real reporting channel, or only principles? Does the language survive the move from a social post to a document that carries legal accountability? And does the FTC actually act? Our position has been that the binding rules on AI in the US are currently being written in courtrooms and state attorneys general offices, not in Washington panels — nothing here changes that. Long term we remain optimistic: a state that builds genuine fluency in this technology is a precondition for the upside, the one where AI compresses drug discovery and extends healthy life. But an institution optimised for arriving first is not the same as one optimised for arriving intact, and the gap between those two goals is exactly where the next few years of transition costs will land.